carboplatin + flavopiridol + paclitaxel

This is a combination chemotherapy regimen consisting of three agents: - **Carboplatin** is a platinum-based chemotherapeutic that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. - **Flavopiridol** (also known as alvocidib) is a synthetic flavonoid and cyclin-dependent kinase (CDK) inhibitor, which blocks cell cycle progression by inhibiting CDKs involved in cell division. - **Paclitaxel** (Taxol) is a microtubule-stabilizing agent that disrupts mitosis by preventing microtubule depolymerization. The combination aims to exploit complementary mechanisms of action for enhanced antitumor activity. While the pairing of carboplatin and paclitaxel is well established for various solid tumors such as ovarian, lung, breast, endometrial, and cervical cancers[1][3][4][5], the addition of flavopiridol introduces targeted inhibition of cell cycle regulators. This triple-drug regimen has been explored primarily in clinical research settings for its potential synergistic effects on cancer cells through simultaneous induction of DNA damage (carboplatin), disruption of mitosis (paclitaxel), and inhibition of cell cycle progression (flavopiridol).